Fast-growing lung health startups aim to redefine early interception of lung cancer using artificial intelligence (AI) decision support software
Optellum, an AI company for lung health, has launched a strategic collaboration with Johnson & Johnson’s Lung Cancer Initiative... Through collaboration, Optellum will apply an AI-powered clinical decision support platform with the goal of increasing lung cancer survival through early intervention and prevention.
Lung cancer is the most common type of cancer in the world and is the leading cause of cancer death. About 1.8 million people die from lung cancer each year worldwide. The current 5-year survival rate is only 20%. This is primarily due to most patients diagnosed after the disease has progressed to an advanced stage (stage III or IV). However, the survival rate of small tumors treated with stage IA can reach as high as 90%.
At the heart of the collaboration is Optellum’s commercial software, Virtual Nodule Clinic. This includes digital biomarkers that utilize AI based on neural networks and image analysis. Identify and track patients at risk and assign lung cancer prediction scores to lung nodules. This is a small lesion that is frequently detected on computed tomography (CT) scans of the chest, which may or may not be cancerous. Optellum AI is used to promote accurate early diagnosis and optimal treatment decisions with the goal of treating patients early, potentially precancerous, and increasing survival.
Optellum software was approved by the U.S. Food and Drug Administration (FDA) in March 2021 and was initially implemented in clinical care by major hospitals across the United States and deployed in some markets in Asia Pacific and Europe. I am. The software has been widely validated in multicenter collaborative studies led by co-authors of clinical guidelines. In FDA-approved clinical studies, all pulmonologists and radiologists who participated in the study showed statistically significant improvements in diagnostic accuracy and consistency, making better clinical management decisions. did.
Optellum’s vision is to redefine early intervention for lung cancer by allowing all patients to be diagnosed and treated at the earliest possible stage of cure. In addition to its lung cancer product portfolio, the company is looking for solutions that apply the same technology platform to other deadly diseases of the lung, such as interstitial lung disease and COPD.
“This collaboration is an important milestone for Optellum.” Dr. Václav Potěšil, Founder and CEO of Optellum, commented. Potěšil continued: “This is a step towards Optellum’s vision of redefining early lung cancer treatment by allowing all clinicians in all hospitals to make the right decisions and provide patients with the best opportunity to fight back. You can get closer. “
Sam Janes, MD, Head of Respiratory Research at UCL Hospital, Vice-Chair of the UK National Lung Cancer Clinical Reference Group, and a member of the Optellum Medical Advisory Board, commented:
“I think the next step in diagnosing and treating lung cancer is the fusion of new technologies. AI is using imaging, clinical and molecular data (such as liquid biopsy) to help diagnose disease earlier. The key to enabling integration. This fusion of technologies has great potential to help doctors prevent, intercept, and ultimately treat patients with early-stage lung cancer. “
For more information, please visit: Optellum.com..
 The corporation of Johnson & Johnson’s Lung Cancer Initiative is Johnson & Johnson Enterprise Innovation, Inc.
Optellum announces strategic collaboration with Johnson & Johnson’s Lung Cancer Initiative to apply AI to transform early lung cancer treatment-
Source link Optellum announces strategic collaboration with Johnson & Johnson’s Lung Cancer Initiative to apply AI to transform early lung cancer treatment-